The Patent Finder
HB

Hydra Biosciences, Inc.

First filing 2005
OverviewNotableFeesChangesFamiliesPatent listSources & methods

3 patents currently held

31 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2030. from the record

Of the 31 now held by other companies, 15 name Boehringer Ingelheim International GmbH as their current owner, and 16 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
May 2030
Next term end
3
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
Cited by 37 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by Orvida Pharma Ltd.
Ends Jan 2028 · High confidence
Also notable
The most cited patent in this portfolio, cited by 43 later US patents, top 25% of utility patents granted in 2012 in our data. Protection runs to 2029.
Ends Jul 2029 · High confidence
Also notable
The largest patent family in this portfolio, 7 related applications, renewed at every maintenance window due so far. Protection runs to 2034.
Ends Mar 2034 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

  • 1 term has ended since Aug 18, 2026

What they patent

The 2 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 3 of 3

PatentTitleStatusExpiresConfidence
US 8,318,728Compounds and Compositions for Treating Chemical Warfare Agent-Induced Injuries
In force
 · High confidence
In forceHigh confidence
US 8,394,840Modulators of sperm hypermotility and uses thereof
In force
 · High confidence
In forceHigh confidence
US 9,440,973PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 3: 31 patents in force now held by others · 19 patents ended · 29 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited